COVID-19: booster(s) vs. hospitalization and Intensive Care Unit admission

dc.contributor.authorToprak, O. Baydar
dc.contributor.authorAkpolat, T.
dc.contributor.authorUzun, O.
dc.contributor.authorDeniz, P. Pinar
dc.contributor.authorKokturk, N.
dc.contributor.authorVarol, A.
dc.contributor.authorItil, B. Oya
dc.date.accessioned2026-08-12T16:57:52Z
dc.date.issued2023
dc.departmentFırat Üniversitesi
dc.description.abstractOBJECTIVE: As the pandem-ic continues, different vaccine protocols have been implemented to maintain the protection of vaccines and to provide protection against new variants. The aim of this study was to as-sess hospitalized patients' vaccination status and document the efficacy of boosters.PATIENTS AND METHODS: The patients that were hospitalized due to COVID-19 were enrolled from 28 hospitals in Turkey for five months from September 2021. 5,331 confirmed COVID-19 pa-tients from collaborating centers were random-ly enrolled to understand/estimate the distri-bution of vaccination status in hospitalized pa-tients and to compare the efficacy of vaccina-tion/booster protocols.RESULTS: 2,779 men and 2,552 women of which 2,408 (45.2%) were admitted to Intensive Care Units participated in this study. It was found that the highest risk reduction for all age groups was found in groups that received 4 doses. Four doses of vaccination for every 3.7 people under 50 years of age, for every 5.7 people in the 50-64 age group, and for every 4.3 people over 65 years of age will prevent 1 patient from being admitted to intensive care. Regardless of the type of vaccine, it was found that the risk of ICU hospitalization decreased in those who were vaccinated compared to those who were not vaccinated. Regardless of the type of vaccine, the ICU risk was found to decrease 1.25-fold in those who received 1 or 2 doses of vaccine, 1.18-fold in those who received 3 dos-es, and 3.26-fold in those who received 4 doses.CONCLUSIONS: The results suggested that the addition of a fourth dose is more effective in preventing intensive unit care even in disad-vantaged.
dc.description.sponsorshipTurkish Thoracic Society
dc.description.sponsorshipThe authors want to thank Turkish Thoracic Society for funding this study.
dc.identifier.endpage2142
dc.identifier.issn1128-3602
dc.identifier.issue5
dc.identifier.orcid0000-0001-7320-976X
dc.identifier.orcid0000-0003-3104-9205
dc.identifier.orcid0000-0003-0183-6232
dc.identifier.orcid0000-0001-5308-4488
dc.identifier.orcid0000-0003-3814-0474
dc.identifier.orcid0000-0002-3542-3906
dc.identifier.orcid0000-0002-0780-6176
dc.identifier.pmid36930513
dc.identifier.scopus2-s2.0-85150666602
dc.identifier.scopusqualityN/A
dc.identifier.startpage2132
dc.identifier.urihttps://hdl.handle.net/11508/46634
dc.identifier.volume27
dc.identifier.wosWOS:000960863600014
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherVerduci Publisher
dc.relation.ispartofEuropean Review for Medical and Pharmacological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectCOVID-19
dc.subjectBooster
dc.subjectVaccination
dc.subjectHospitalization
dc.subjectVaccine effectiveness
dc.titleCOVID-19: booster(s) vs. hospitalization and Intensive Care Unit admission
dc.typeArticle

Dosyalar